<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDROMORPHONE HYDROCHLORIDE</span><br/>(hye-droe-mor'fone)<br/><span class="topboxtradename">Dilaudid, </span><span class="topboxtradename">Dilaudid-HP<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg, 3 mg, 4 mg, 8 mg tablets; 12 mg, 16 mg, 24 mg, 32 mg extended-release capsules; 5 mg/5 mL oral liquid; 1 mg/mL, 2 mg/mL, 4 mg/mL, 10 mg/mL injection; 3 mg suppositories</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic derivative structurally similar to morphine but with 810 times more potent analgesic effect. Has more
         rapid onset and shorter duration of action than morphine and is reported to have less hypnotic action and less tendency to
         produce nausea and vomiting.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Is a narcotic analgesic which controls mild to moderate pain. Has antitussive properties.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of moderate to severe pain and control of persistent nonproductive cough.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Intolerance to opiate agonists; pregnancy (category C), acute bronchial asthma, COPD, upper airway obstruction, decreased
         respiratory reserve, severe respiratory depression, opiate-naïve patients.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Abrupt discontinuation, alcoholism; angina; biliary tract disease; older adults; epidural administration; GI disease, GI obstruction;
         head trauma; heart failure; hepatic disease; hypotension, hypovolemia, oliguria, prostatic hypertrophy; pulmonary disease;
         renal disease, renal impairment; paralytic ileus; increased intracranial pressure; inflammatory bowel disease; labor; latex
         hypersensitivity; obstetric delivery; bladder obstruction; cardiac arrhythmias, cardiac disease; respiratory depression; seizure
         disorder, seizures; substance abuse; surgery; ulcerative colitis; urethral stricture, urinary retention; lactation, neonates,
         and infants 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/SC/IM/IV</span> 14 mg q46h prn. <span class="rdroute">Extended release</span> 1232 mg q24h (see prescribing information for conversion from other opioid analgesics) <span class="rdroute">Rectal</span> 3 mg q46h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.030.08 mg/kg q46h (max: 5 mg/dose) <span class="rdroute">IV</span> 0.015 mg/kg q46h<br/><br/><span class="indicationtitle">Antitussive</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg q34h prn<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>612 y</i>, 0.5 mg q34h prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li> 				Note: A fixed schedule when narcotic therapy is initiated provides more effective management than a prn schedule. 			</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p>IV administration to infants, children: Verify correct IV concentration and rate of infusion with physician.</p>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each dose in at least 5 mL of sterile water or NS.   <span class="methodtype">IV Infusion:</span> Using Dilaudid-HP, reconstitute 250 mg dry powder vial immediately prior to use with 25 mL sterile water for injection to
                  yield 10 mg/mL. Final dilution of Dilaudid-HP 250 and HP 500 (supplied 500 mg/50 mL) must be ordered by physician.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 2 mg or fraction thereof over 35 min.  <span class="methodtype">IV Infusion:</span> Both final volume and rate of infusion must be ordered by physician.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Prochlorperazine,</b> <b>sodium bicarbonate,</b> <b>thiopental.</b> <span class="incompattype">Y-site:</span> <b>Minocycline,</b> <b>prochlorperazine,</b> <b>tetracycline.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>A slight discoloration in ampules or multidose vials causes no loss of potency.</li>
<li>Store in tight, light-resistant containers at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea, vomiting, constipation. <span class="typehead">CNS:</span> Euphoria, dizziness, sedation, <span class="speceff-common">drowsiness</span>. <span class="typehead"> CV:</span>  Hypotension, bradycardia or tachycardia. <span class="typehead">Respiratory:</span> <span class="speceff-life">Respiratory depression</span>. <span class="typehead">Special Senses:</span> Blurred vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> compound sedation and CNS depression. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may increase sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60% absorbed from GI tract. <span class="typehead">Onset:</span> 15 min IV, 30 min PO/rectal. <span class="typehead">Peak:</span> 3090 min. <span class="typehead">Duration:</span> 34 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-life:</span> 23 h; 18 h extended release. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Note baseline respiratory rate, rhythm, and depth and size of pupils before administration. Respirations of 12/min or less
            and mitosis are signs of toxicity. Withhold drug and promptly notify physician.
         </li>
<li>Monitor vital signs at regular intervals. Drug-induced respiratory depression may occur even with small doses and increases
            progressively with higher doses.
         </li>
<li>Assess effectiveness of pain relief 30 min after medication administration.</li>
<li>Monitor drug effects carefully in older adult or debilitated patients and those with impaired renal and hepatic function.</li>
<li>Assess effectiveness of cough. Drug depresses cough and sigh reflexes and may induce atelectasis, especially in postoperative
            patients and those with pulmonary disease.
         </li>
<li> 							Note: Nausea and orthostatic hypotension most often occur in ambulatory patients or when a supine patient assumes the head-up position. 						</li>
<li>Monitor I&amp;O ratio and pattern. Assess lower abdomen for bladder distension. Report oliguria or urinary retention.</li>
<li>Monitor bowel pattern; drug-induced constipation may require treatment.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Request medication at the onset of pain and do not wait until pain is severe.</li>
<li>Use caution with activities requiring alertness; drug may cause drowsiness, dizziness, and blurred vision.</li>
<li>Avoid alcohol and other CNS depressants while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>